QIAGEN enters discussion to explore potential strategic alternatives

Nov. 18, 2019

QIAGEN announced it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company.

The Supervisory Board and the Management Board of QIAGEN, in accordance with their fiduciary duties and as part of the review of potential strategic alternatives, are starting discussions with interested parties. These discussions aim to explore potential strategic alternatives that could provide greater value creation opportunities than the already strong stand-alone growth prospects for the Company, taking into consideration the interests of QIAGEN’s stakeholders including its shareholders.

There is no guarantee or certainty that these discussions will lead to a recommended firm offer to all shareholders of the Company.

QIAGEN remains committed to serving its more than 500,000 customers worldwide with a portfolio of Sample to Insight solutions focused on exciting areas of molecular testing, executing on strategies for growth while continuing to exercise financial discipline.

Visit QIAGEN for the release

Events

MLO's Virtual Forum

Nov. 1, 2023 - Nov. 30, 2023
Events

AACC

July 23, 2023 - July 27, 2023
Events

MLO's Virtual Forum

June 1, 2023 - June 30, 2023
Events

ASCLS-AGT-SAFMLS

June 26, 2023 - June 30, 2023